Chaka Chipawe, NP
Adult Health · White Lake, MINPI 1104378264
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 468 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 12.5% — the pattern of someone who eats at a lot of different presentations. Among adult health clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 468 payments — averaging $19.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Indivior Inc.$919
- Novo Nordisk$882
- AstraZeneca$670
- USWM, LLC$660
- GSK$597
- plus $4K from 30 others
What the payments were for
- Food & beverage$9,23499%
- Education$611%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 57 | $1,160 |
| Indivior Inc. | 39 | $919 |
| Novo Nordisk | 47 | $882 |
| AstraZeneca(2 entities) | 40 | $670 |
| USWM, LLC | 35 | $660 |
| GSK | 25 | $597 |
| Braeburn Inc. | 24 | $494 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 37 | $494 |
| Vanda Pharmaceuticals Inc. | 19 | $447 |
| Lilly USA, LLC | 24 | $388 |
| Pfizer | 17 | $344 |
| Alkermes, Inc. | 16 | $332 |
| Axsome Therapeutics, Inc. | 10 | $275 |
| Boehringer Ingelheim | 15 | $231 |
| Novartis | 10 | $201 |
| Amgen | 5 | $168 |
| Johnson & Johnson | 2 | $150 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $131 |
| Orexo US, Inc. | 5 | $120 |
| Sanofi-aventis U.S. LLC | 6 | $95 |
| Lundbeck LLC | 5 | $93 |
| E.r. Squibb & Sons, L.L.C. | 4 | $81 |
| Collegium Pharmaceutical, Inc. | 3 | $48 |
| Merck | 2 | $38 |
| Amarin Pharma, Inc. | 2 | $35 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $34 |
| Dexcom, Inc. | 2 | $31 |
| Otsuka America Pharmaceutical, Inc. | 2 | $28 |
| Biohaven Pharmaceuticals, Inc. | 1 | $26 |
| Paratek Pharmaceuticals, Inc. | 1 | $24 |
| Pear Therapeutics (US), Inc. | 1 | $22 |
| Redhill Biopharma Inc. | 1 | $21 |
| Abbott | 1 | $19 |
| Baxter Healthcare | 1 | $15 |
| Exact Sciences | 1 | $14 |
| Biodelivery Sciences International, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,295 in reported general payments places this provider in the 95th percentile of 527 adult health providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 57 | $39,908 |
| TrulicityDulaglutide | 17 | $27,738 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 88 | $14,338 |
| EliquisApixaban | 11 | $13,108 |
| Atorvastatin Calcium | 103 | $1,118 |
| Baclofen | 24 | $1,095 |
| Naltrexone Hcl | 31 | $933 |
| Lisinopril | 88 | $863 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 29 | $791 |
| Gabapentin | 75 | $763 |
| Losartan Potassium | 60 | $747 |
| Tamsulosin Hcl | 31 | $603 |
| Omeprazole | 60 | $553 |
| Levothyroxine Sodium | 47 | $542 |
| ClopidogrelClopidogrel Bisulfate | 29 | $532 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $597 | $39,90857 claims |
| Lilly USA, LLCTrulicity | $388 | $27,73817 claims |
| PfizerEliquis | $344 | $13,10811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 527 adult health providers in Michigan.
Other adult health in White Lake
- Jacqueline BrewerSterling Heights$138K
- Linda Morris McCoyGrand Rapids$59K
- Sarita RaoCanton$51K
- Susanne QuallichAnn Arbor$42K
- Nancy BermanSouthfield$39K
- Michelle MillerQuincy$24K
- Deniene KingAnn Arbor$14K
- Adama JohnsonEastpointe$14K
- Bridget BonelloWyandotte$13K
- Mary KaiserKalamazoo$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.